{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T11:54:59Z","timestamp":1719230099369},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170369","82170369","82170369","82170369","82170369","82170369","82170369","82170369","82170369"],"award-info":[{"award-number":["82170369","82170369","82170369","82170369","82170369","82170369","82170369","82170369","82170369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Apatinib is a novel antiangiogenic agent that targets vascular endothelial growth factor 2. The aim of our study was to explore the efficacy and safety of apatinib in the treatment of patients with recurrence or metastasis (R\/M) inoperable head and neck squamous cell carcinoma (HNSCC). This multi-center retrospective study analyzed 53 cases of recurrent or metastatic inoperable HNSCC who had progressed or recurred after undergoing standard radiotherapy, chemotherapy, and immunotherapy treated with apatinib from March 2017 to August 2021. Patients continued apatinib until the time of disease progression or onset of intolerable adverse events. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), and disease control rate (DCR) and incidence of adverse events. Univariable and multivariable analyses were performed to determine prognostic factors. The main adverse events were counted, and the severity of the adverse reactions was evaluated. Fifty-three patients with recurrent or metastatic inoperable R\/M HNSCC who had progressed or recurred after standard radiotherapy, chemotherapy, and immunotherapy were included. The ORR was 15.1%, and the DCR was 86.8%. The median PFS was 4.4\u00a0months (95% confidence interval [CI] 3.7\u20135.0\u00a0months) and the median OS was 6.6\u00a0months (95% CI 5.3\u20137.9\u00a0months). The number of apatinib lines was an influencing factor for both PFS and OS, and the Eastern Cooperative Oncology Group (ECOG) score, tumor differentiation, and apatinib duration were only the influencing factors for OS. Of these, only the ECOG score was an independent predictor of OS. The most common adverse reactions were hypertension (39.6%), hand-foot syndrome (32.1%), fatigue (32.1%), oral ulcers (28.3%), and nausea and vomiting (20.8%). Most adverse reactions were grade 1 or 2. Apatinib mesylate has good efficacy for recurrent\/metastatic inoperable HNSCC as second-line and above-line treatment. ECOG score was an independent prognostic factors of OS in patients who were treated with apatinib. In addition, the adverse effects of apatinib mesylate were relatively mild.<\/jats:p>","DOI":"10.1038\/s41598-022-20272-x","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T18:10:39Z","timestamp":1667239839000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study"],"prefix":"10.1038","volume":"12","author":[{"given":"Zijing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuangzhuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingbin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"issue":"6","key":"20272_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"20272_CR2","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/jamaoncol.2017.0973","volume":"3","author":"JE Leeman","year":"2017","unstructured":"Leeman, J. E. et al. Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol. 3(11), 1487\u20131494. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0973 (2017).","journal-title":"JAMA Oncol."},{"issue":"10","key":"20272_CR3","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/annonc\/mdq077","volume":"21","author":"R Mesia","year":"2010","unstructured":"Mesia, R. et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 21(10), 1967\u20131973. https:\/\/doi.org\/10.1093\/annonc\/mdq077 (2010).","journal-title":"Ann. Oncol."},{"issue":"11","key":"20272_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa0802656 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"20272_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 394(10212), 1915\u20131928. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7 (2019).","journal-title":"Lancet"},{"issue":"7","key":"20272_CR6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17(7), 956\u2013965. https:\/\/doi.org\/10.1016\/s1470-2045(16)30066-3 (2016).","journal-title":"Lancet Oncol."},{"issue":"10167","key":"20272_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/s0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet 393(10167), 156\u2013167. https:\/\/doi.org\/10.1016\/s0140-6736(18)31999-8 (2019).","journal-title":"Lancet"},{"issue":"12","key":"20272_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/14712598.2021.1830969","volume":"20","author":"DSC Ng","year":"2020","unstructured":"Ng, D. S. C. et al. Ranibizumab for myopic choroidal neovascularization. Expert Opin. Biol. Ther. 20(12), 1385\u20131393. https:\/\/doi.org\/10.1080\/14712598.2021.1830969 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"20272_CR9","first-page":"47","volume":"18","author":"K Fujita","year":"2007","unstructured":"Fujita, K. et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol. Rep. 18(1), 47\u201351 (2007).","journal-title":"Oncol. Rep."},{"issue":"9","key":"20272_CR10","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1200\/jco.2010.33.3591","volume":"29","author":"A Argiris","year":"2011","unstructured":"Argiris, A. et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J. Clin. Oncol. 29(9), 1140\u20131145. https:\/\/doi.org\/10.1200\/jco.2010.33.3591 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"20272_CR11","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/jco.19.00555","volume":"37","author":"A Argiris","year":"2019","unstructured":"Argiris, A. et al. Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer. J. Clin. Oncol. 37(34), 3266\u20133274. https:\/\/doi.org\/10.1200\/jco.19.00555 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"20272_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","volume":"102","author":"S Tian","year":"2011","unstructured":"Tian, S. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102(7), 1374\u20131380. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01939.x (2011).","journal-title":"Cancer Sci."},{"issue":"32","key":"20272_CR13","doi-asserted-by":"publisher","first-page":"52813","DOI":"10.18632\/oncotarget.17264","volume":"8","author":"QX Peng","year":"2017","unstructured":"Peng, Q. X. et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget 8(32), 52813\u201352822. https:\/\/doi.org\/10.18632\/oncotarget.17264 (2017).","journal-title":"Oncotarget"},{"key":"20272_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000798","author":"L Xie","year":"2020","unstructured":"Xie, L. et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: A single-arm, open-label, phase 2 trial. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-000798 (2020).","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"20272_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jitc-2020-000696","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial. J. Immunother. Cancer 8(1), 25. https:\/\/doi.org\/10.1136\/jitc-2020-000696 (2020).","journal-title":"J. Immunother. Cancer"},{"issue":"34","key":"20272_CR16","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/jco.20.01920","volume":"38","author":"C Lan","year":"2020","unstructured":"Lan, C. et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial. J. Clin. Oncol. 38(34), 4095\u20134106. https:\/\/doi.org\/10.1200\/jco.20.01920 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"20272_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/cac2.12119","volume":"40","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun. (Lond.) 40(12), 711\u2013720. https:\/\/doi.org\/10.1002\/cac2.12119 (2020).","journal-title":"Cancer Commun. (Lond.)"},{"issue":"2","key":"20272_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","volume":"16","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial. J. Thorac. Oncol. 16(2), 299\u2013309. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.002 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"20272_CR19","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s10637-020-00925-2","volume":"38","author":"L Li","year":"2020","unstructured":"Li, L. et al. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: Data from an open-label, single-arm, exploratory study. Investig. New Drugs 38(6), 1847\u20131853. https:\/\/doi.org\/10.1007\/s10637-020-00925-2 (2020).","journal-title":"Investig. New Drugs"},{"issue":"3","key":"20272_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ijc.28201","volume":"134","author":"ML Gillison","year":"2014","unstructured":"Gillison, M. L. et al. Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int. J. Cancer 134(3), 497\u2013507. https:\/\/doi.org\/10.1002\/ijc.28201 (2014).","journal-title":"Int. J. Cancer"},{"issue":"5","key":"20272_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cncr.24123","volume":"115","author":"KA Gold","year":"2009","unstructured":"Gold, K. A., Lee, H. Y. & Kim, E. S. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115(5), 922\u2013935. https:\/\/doi.org\/10.1002\/cncr.24123 (2009).","journal-title":"Cancer"},{"key":"20272_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fonc.2018.00310","volume":"8","author":"MD Forster","year":"2018","unstructured":"Forster, M. D. & Devlin, M. J. Immune checkpoint inhibition in head and neck cancer. Front. Oncol. 8, 310. https:\/\/doi.org\/10.3389\/fonc.2018.00310 (2018).","journal-title":"Front. Oncol."},{"issue":"19","key":"20272_CR23","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375(19), 1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"20272_CR24","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/annonc\/mdz388","volume":"30","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): An open-label, randomised phase III trial. Ann. Oncol. 30(11), 1831\u20131839. https:\/\/doi.org\/10.1093\/annonc\/mdz388 (2019).","journal-title":"Ann. Oncol."},{"issue":"11","key":"20272_CR25","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/jco.2008.17.0530","volume":"27","author":"JS Stewart","year":"2009","unstructured":"Stewart, J. S. et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol. 27(11), 1864\u20131871. https:\/\/doi.org\/10.1200\/jco.2008.17.0530 (2009).","journal-title":"J. Clin. Oncol."},{"key":"20272_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","volume":"107","author":"DP Zandberg","year":"2019","unstructured":"Zandberg, D. P. et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur. J. Cancer 107, 142\u2013152. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.015 (2019).","journal-title":"Eur. J. Cancer"},{"issue":"24","key":"20272_CR27","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/jco.2006.10.2871","volume":"25","author":"C Elser","year":"2007","unstructured":"Elser, C. et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25(24), 3766\u20133773. https:\/\/doi.org\/10.1200\/jco.2006.10.2871 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"20272_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1200\/jco.2009.23.8584","volume":"28","author":"JP Machiels","year":"2010","unstructured":"Machiels, J. P. et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006\u201301. J. Clin. Oncol. 28(1), 21\u201328. https:\/\/doi.org\/10.1200\/jco.2009.23.8584 (2010).","journal-title":"J. Clin. Oncol."},{"key":"20272_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li, J. et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10, 529. https:\/\/doi.org\/10.1186\/1471-2407-10-529 (2010).","journal-title":"BMC Cancer"},{"issue":"19","key":"20272_CR30","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.can-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099\u20137109. https:\/\/doi.org\/10.1158\/0008-5472.can-04-1443 (2004).","journal-title":"Cancer Res."},{"issue":"1","key":"20272_CR31","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327\u2013337 (2003).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"20272_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s10637-015-0293-8","volume":"33","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki, P. L. et al. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investig. New Drugs 33(6), 1248\u20131256. https:\/\/doi.org\/10.1007\/s10637-015-0293-8 (2015).","journal-title":"Investig. New Drugs"},{"issue":"5706","key":"20272_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58\u201362. https:\/\/doi.org\/10.1126\/science.1104819 (2005).","journal-title":"Science"},{"key":"20272_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010018","author":"A De Leo","year":"2020","unstructured":"De Leo, A., Ugolini, A. & Veglia, F. Myeloid cells in glioblastoma microenvironment. Cells https:\/\/doi.org\/10.3390\/cells10010018 (2020).","journal-title":"Cells"},{"issue":"17","key":"20272_CR35","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/cncr.33626","volume":"127","author":"X Ruan","year":"2021","unstructured":"Ruan, X. et al. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study. Cancer 127(17), 3163\u20133171. https:\/\/doi.org\/10.1002\/cncr.33626 (2021).","journal-title":"Cancer"},{"key":"20272_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105222","volume":"115","author":"L Huang","year":"2021","unstructured":"Huang, L. et al. Efficacy and safety of apatinib in recurrent\/metastatic nasopharyngeal carcinoma: A pilot study. Oral Oncol. 115, 105222. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105222 (2021).","journal-title":"Oral Oncol."},{"issue":"10","key":"20272_CR37","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cncr.32762","volume":"126","author":"SE Kochanny","year":"2020","unstructured":"Kochanny, S. E. et al. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent\/metastatic head and neck squamous cell carcinoma. Cancer 126(10), 2146\u20132152. https:\/\/doi.org\/10.1002\/cncr.32762 (2020).","journal-title":"Cancer"},{"issue":"4","key":"20272_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.ccr-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez, C. P. et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin. Cancer Res. 26(4), 837\u2013845. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2214 (2020).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20272-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T18:15:30Z","timestamp":1667240130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20272-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20272"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20272-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"3 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18327"}}